Skip to main content
Fig. 9 | BMC Medical Genomics

Fig. 9

From: A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learning

Fig. 9

Macrophages-related signature (MRS)-based treatment strategy for ovarian cancer. The IC50 values of 5-Fluorouracil (A), Cisplatin(B), Fludarabine(C), Cyclophosphamide (D), Fulvestrant (E), Mitoxantrone (F), Topotecan(G), Venetoclax (H), Bortezomib (I), Erlotinib (J), Savolitinib (K), Selumetinib (L) in ovarian cancer patients with high and low risk score

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us